Kategorien
Aktien

Pharmaxis Ltd 0,09 EUR +3,63% 

SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Tradegate System der Deutsche Börse AG (60%)
Börse Tradegate System der Deutsche Börse AG (60%)
Symbol UUD
EUR
↓
  • Pharmaxis Ltd
    Börse Australian Securities Exchange Sydney
    ISIN AU000000PXS5 WKN: 254463
    Symbol PXS
  • Pharmaxis Ltd
    Börse Börse Frankfurt
    Symbol UUD
    EUR
  • Pharmaxis Ltd
    Börse Börse München
    Symbol UUD
    EUR
  • Pharmaxis Ltd
    Börse Börse Stuttgart
    Symbol UUD
    EUR
  • Pharmaxis Ltd
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol UUD
    EUR
  • Pharmaxis Ltd
    Börse Börse Düsseldorf
    Symbol UUD
    EUR
  • Pharmaxis Ltd
    Börse Quotrix System der Börse Düsseldorf
    Symbol UUD
    EUR
  • Pharmaxis Ltd
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    ISIN AU000000PXS5 WKN: 254463
    Symbol PXS
    USD
  • Pharmaxis Ltd
    Börse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
    USD
  • ISIN AU000000PXS5 WKN: 254463
    Symbol PXS
    AUD
  • Pharmaxis Ltd
    Börse Freiverkehr OTC
Symbol UUD
Währung EUR
Börse Tradegate System der Deutsche Börse AG (60%) Zeitzone: Australia/Sydney
Marktkapitalisierung 38.000.000
Mitarbeiter 69

18 News & Informationen zur Pharmaxis Ltd Aktie

  • Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
    stockhead.com.au

    Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

    Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs for ASX health stocks.

  • Pharmaxis Treatment To Prevent Wound And Burns Scars Clears Phase 1 Trial
    thestreet.com

    Pharmaxis Treatment To Prevent Wound And Burns Scars Clears Phase 1 Trial

    Topical treatment safe and well tolerated in study of healthy volunteers
    Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic

  • Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
    prnewswire.com

    Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

    /PRNewswire/ — Pharmaxis (ASX: PXS) today announced that its novel topical drug treatment for scarring has delivered positive Phase 1 clinical trial results…

  • ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in
    stockhead.com.au

    ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in

    ASX Healthcare (XHJ) index finished the week up 2.23%, compared to the broader market which ended 2.20% lower. CSL and Cochlear reported earnings.

  • Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
    stockhead.com.au

    Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

    Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

  • Proactive news headlines including Antilles Gold, Pharmaxis, Tempus Resources and Horizon Minerals
    financialpost.com

    Proactive news headlines including Antilles Gold, Pharmaxis, Tempus Resources and Horizon Minerals

    Sydney, Aug. 17, 2021 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the…

  • ASX Health Stocks: Osprey jumps 8% on solid first half; Bard1 concludes successful study
    stockhead.com.au

    ASX Health Stocks: Osprey jumps 8% on solid first half; Bard1 concludes successful study

    ASX health stock Osprey Medical (ASX:OSP) climbed by almost 8%, after the company reported a 33% increase in first half revenue to US$1.1m.

  • Pharmaxis (ASX:PXS) grants exclusive option to develop Orbital inhaler
    themarketherald.com.au

    Pharmaxis (ASX:PXS) grants exclusive option to develop Orbital inhaler

    Clinical-stage drug developer Pharmaxis (ASX:PXS) has granted Aptar Pharma the exclusive option to acquire worldwide rights to its Orbital inhaler.

  • Market highlights and 5 ASX small caps to watch on Tuesday
    stockhead.com.au

    Market highlights and 5 ASX small caps to watch on Tuesday

    Without a strong lead from global markets, the ASX 200 looks set to open in the red with futures markets currently pointing to a ~0.4% drop.

  • Rise and Shine: What you need to know before the ASX opens
    stockhead.com.au

    Rise and Shine: What you need to know before the ASX opens

    Rise and Shine brings all you need to know about before the ASX market open on Tuesday, August 17, including IPOs, trading halts and yesterday's moves.

  • ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
    stockhead.com.au

    ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension

    Micro cap medical device company dorsaVi (DVL) took the limelight this morning, jumping by 15% after saying that it has extended the contract with Medtronic

  • Pharmaxis (ASX:PXS) drug decreases tumour burden in liver cancer model
    themarketherald.com.au

    Pharmaxis (ASX:PXS) drug decreases tumour burden in liver cancer model

    Clinical-stage drug developer Pharmaxis (ASX:PXS) has reported encouraging results from studies of its anti-cancer drug PXS-5505 in a pre-clinical model of liver cancer.

  • Market Highlights and 5 ASX Small Caps to watch on Thursday
    stockhead.com.au

    Market Highlights and 5 ASX Small Caps to watch on Thursday

    ASX small caps to watch on Thursday 5 August, and highlights from Wall Street overnight. ASX stocks include Immutep (IMM), Neuren Pharma (NEU).

  • Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
    stockhead.com.au

    Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

    ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the benchmark rose by 3%.

  • Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
    stockhead.com.au

    Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

    Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

  • ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery
    stockhead.com.au

    ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery

    ASX healthcare stocks finished the week down 0.22 per cent, compared to the broader market which ended flat. Nanosonics (NAN) was one of the picks this week

  • Pharmaxis (ASX:PXS) gets first results from bone marrow cancer trial
    themarketherald.com.au

    Pharmaxis (ASX:PXS) gets first results from bone marrow cancer trial

    Pharmaxis (ASX:PXS) has received initial data from its phase 1c clinical trial that's studying a potential new treatment for myelofibrosis.

  • Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
    stockhead.com.au

    Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough

    Stockhead reports ASX biotech and healthcare roundup for the last fortnight. Stocks include Actinogen (ACW), Suda Pharma (SUD), and Patrys (PAB).

Schreibe einen Kommentar

Community Kommentar Anonymer Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile

  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Dir gefallen die Informationen zu Pharmaxis Ltd?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba

Dir gefallen die Informationen zu Pharmaxis Ltd?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero

Dir gefallen die Informationen zu Pharmaxis Ltd?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Pharmaxis Ltd?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Unternehmen aus den Branchen Gesundheit und Wissenschaft

Kategorien
Aktien
Kura Oncology
Zum Portrait “Kura Oncology”
Kategorien
Aktien
CASI Pharmaceuticals
Zum Portrait “CASI Pharmaceuticals”
Kategorien
Aktien
Moleculin Biotech Inc
Zum Portrait “Moleculin Biotech Inc”
Kategorien
Aktien
Exact Sciences Corp
Zum Portrait “Exact Sciences Corp”